Aurora Cannabis has urged its shareholders to reject Curaleaf Holdings' unsolicited $272 million takeover offer, calling parts of the U.S. operator's pitch inaccurate.
The Edmonton, Alberta-based medical cannabis company issued a statement Monday correcting what it described as misleading claims from Curaleaf. Aurora's board also announced the formation of a special committee to evaluate the hostile bid.
The pushback marks an escalation in what could become one of the cannabis industry's most contentious cross-border acquisition battles. Aurora operates in 25 countries with a focus on medical cannabis markets, while Curaleaf is one of the largest U.S. multi-state operators with 152 retail locations.
The Valuation Dispute
Aurora's special committee will assess whether Curaleaf's offer accurately reflects the Canadian company's value. The $272 million bid values Aurora's shares at a significant discount to where the company traded earlier this year, according to market data.
Curaleaf first announced its unsolicited offer in early January, positioning the deal as a chance to create a "global cannabis powerhouse." But Aurora's board appears unconvinced that the proposed terms serve shareholders' interests.
The timing is notable. Aurora has been restructuring its operations over the past two years, exiting unprofitable markets and focusing on higher-margin medical cannabis products. The company reported improved cash flow in its most recent quarterly earnings, though it remains unprofitable.
Cross-Border Complications
Any deal between the two companies would face regulatory hurdles. U.S. cannabis operators like Curaleaf cannot be listed on major U.S. exchanges due to federal prohibition, while Aurora trades on the Nasdaq. A merger would likely require complex corporate structures to navigate conflicting legal frameworks.
Aurora also pointed to specific inaccuracies in Curaleaf's public statements about the offer, though the company did not detail which claims it disputes. That suggests Aurora may release a more comprehensive rebuttal in coming days.
The Canadian cannabis sector has seen significant consolidation since legalization in 2018, with companies like Canopy Growth and Tilray Brands absorbing smaller competitors. But hostile takeovers remain rare in the industry.
What's Next
Aurora's special committee will evaluate the offer and provide a formal recommendation to shareholders. The board could also seek alternative buyers or propose a strategic plan to boost shareholder value independently.
Curaleaf has not yet responded to Aurora's Monday statement. The U.S. company could sweeten its offer, take the bid directly to shareholders, or withdraw entirely.
Shareholders will likely watch for Aurora's next earnings report and any updates on its international expansion strategy. The company has license agreements in Germany, Australia, and several other medical cannabis markets that could prove valuable to a global acquirer.
The battle also comes as U.S. cannabis companies eye international expansion opportunities ahead of potential federal legalization. Several MSOs have explored entry into European medical markets, though most remain focused on domestic growth.
This article is based on original reporting by mjbizdaily.com.
